查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1785384

mRNA 疫苗市場－全球產業規模、佔有率、趨勢、機會和預測，按 mRNA 類型、應用、地區和競爭細分，2020-2030 年

mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By mRNA Type, By Application, Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球mRNA疫苗市值為114.5億美元，預計2030年將達到183.7億美元，預測期內複合年成長率為8.34%。受新冠疫苗成功及該技術潛力不斷擴大的推動，全球mRNA疫苗市場經歷了快速成長。例如，根據世界衛生組織的數據，心血管疾病（CVD）是世界主要死因，每年約奪走1,790萬人的生命。心血管疾病包括心臟和血管疾病，大多數死亡是由心臟病發作和中風引起的，通常影響70歲以下的人。

市場概覽
預測期 2026-2030
2024年市場規模 114.5億美元
2030年市場規模 183.7億美元
2025-2030 年複合年成長率 8.34%
成長最快的領域 COVID-19 m RNA 疫苗
最大的市場 北美洲

mRNA疫苗使用合成的信使RNA來引導細胞產生觸發免疫反應的蛋白質。與傳統疫苗平台相比，這種方法可以加快開發和生產速度。市場不再局限於傳染病，因為正在進行的研究正在探索mRNA在癌症免疫治療、遺傳性疾病和自體免疫疾病的應用。脂質奈米顆粒遞送系統的進步提高了mRNA疫苗的穩定性和效率，為治療創新開闢了新的機會。各公司正大力投資擴展mRNA研究管道和生產基礎設施，以滿足長期需求。監管機構也不斷調整，以適應mRNA技術的快速發展。大眾對mRNA疫苗的認知度和接受度的提高，進一步推動了其在不同地區的應用。儘管冷鏈物流和高生產成本等挑戰依然存在，但隨著新進業者和策略合作的推進，市場仍在不斷發展。隨著技術的成熟，mRNA疫苗有望成為現代預防和治療醫學的基石，提供有針對性、個人化和可擴展的醫療保健解決方案。

關鍵市場促進因素

快速疫苗研發需求不斷成長

主要市場挑戰

冷鍊和儲存要求

主要市場趨勢

疫苗以外的治療領域多元化發展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：臨床試驗分析

第5章：顧客之聲

第6章：全球mRNA疫苗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依 mRNA 類型（核苷修飾 mRNA、未修飾 mRNA、自擴增 mRNA）
    • 依應用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司 (20242)
  • 產品市場圖
    • 依 mRNA 類型
    • 按應用
    • 按地區

第7章：北美mRNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲mRNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區mRNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美mRNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲 mRNA 疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 14 章：全球 mRNA 疫苗市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • CureVac NV
  • Daiichi Sankyo Company Limited.
  • Ethris GmbH
  • GlaxoSmithKline plc
  • Gennova Biopharmaceuticals Ltd
  • Moderna, Inc.
  • Pantherna Therapeutics GmbH
  • Providence Therapeutics

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 14521

Global mRNA Vaccine Market was valued at USD 11.45 billion in 2024 and is expected to reach USD 18.37 Billion by 2030 with a CAGR of 8.34% during the forecast period. The global mRNA Vaccine market has experienced rapid growth driven by the success of COVID-19 vaccines and the expanding potential of the technology. For instance, according to WHO, cardiovascular diseases (CVDs) are the world's leading cause of death, claiming around 17.9 million lives annually. They include heart and blood vessel disorders, with most deaths caused by heart attacks and strokes, often affecting people under 70.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.45 Billion
Market Size 2030USD 18.37 Billion
CAGR 2025-20308.34%
Fastest Growing SegmentCOVID-19 m RNA Vaccines
Largest MarketNorth America

mRNA Vaccines use a synthetic version of messenger RNA to instruct cells to produce proteins that trigger an immune response. This method enables faster development and manufacturing compared to traditional vaccine platforms. The market is no longer limited to infectious diseases, as ongoing research explores mRNA's application in cancer immunotherapy, genetic disorders, and autoimmune conditions. Advancements in lipid nanoparticle delivery systems have improved the stability and efficiency of mRNA Vaccines, opening new opportunities for therapeutic innovation. Companies are investing heavily in expanding mRNA research pipelines and manufacturing infrastructure to support long-term demand. Regulatory agencies are also adapting to accommodate the rapid pace of development associated with mRNA technologies. The rise in public awareness and acceptance of mRNA Vaccines has further boosted adoption across various geographies. While challenges such as cold chain logistics and high production costs remain, the market continues to evolve with new entrants and strategic collaborations. As technology matures, mRNA Vaccines are expected to become a cornerstone of modern preventive and therapeutic medicine, offering targeted, personalized, and scalable healthcare solutions.

Key Market Drivers

Rising Demand for Rapid Vaccine Development

The rising demand for rapid vaccine development is a major force driving the global mRNA Vaccine market. For instance, on 29 July 2024, Bio-Manguinhos/Fiocruz, one of Latin America's largest vaccine manufacturers, joined CEPI's Global South network. This partnership aims to enhance rapid and equitable vaccine responses to emerging infectious diseases by expanding manufacturing capacity across the Latin American and Caribbean region, strengthening preparedness for future epidemic and pandemic threats through localized production and regional collaboration. Traditional vaccine development can take years, involving complex cultivation, inactivation, or protein purification processes. In contrast, mRNA Vaccines can be designed and produced within weeks once a target pathogen's genetic sequence is known. This speed has become crucial in responding to public health emergencies, as demonstrated during the COVID-19 pandemic. Governments, healthcare organizations, and pharmaceutical companies now recognize the importance of having platforms that allow for quick vaccine adaptation and deployment. mRNA technology offers a flexible and programmable approach. By simply changing the mRNA sequence, developers can target new variants or different diseases without overhauling the entire production process. This flexibility allows for rapid response not only to pandemics but also to emerging infectious threats and seasonal outbreaks. The global health landscape is increasingly shaped by unpredictable disease patterns, making rapid vaccine development a strategic priority.

The ability to accelerate vaccine research and approval timelines also aligns with global efforts to strengthen pandemic preparedness. Investments are being directed toward expanding mRNA production infrastructure, streamlining regulatory pathways, and establishing stockpiles of platform technologies. As demand grows for adaptable and efficient vaccine solutions, mRNA platforms are emerging as essential tools in modern immunization strategies.

Key Market Challenges

Cold chain and storage requirements

Cold chain and storage requirements present a significant challenge to the growth and accessibility of the global mRNA Vaccine market. Unlike traditional vaccines that can often be stored at standard refrigeration temperatures, many first-generation mRNA Vaccines require ultra-cold storage conditions, sometimes as low as -70°C. These extreme requirements create logistical hurdles, especially in developing countries or remote regions where ultra-low temperature freezers and reliable electricity are limited or unavailable. Maintaining the cold chain from manufacturing facilities to administration sites demands specialized equipment, constant temperature monitoring, and trained personnel. Any break in this chain can compromise the integrity and efficacy of the vaccine, leading to waste and reduced immunization rates. This complexity increases distribution costs and slows down deployment, particularly during mass vaccination campaigns or emergency responses.

Efforts are being made to develop mRNA Vaccines that are more stable at higher temperatures, which would simplify storage and handling. Some newer formulations have achieved stability at standard refrigeration levels for limited durations, offering hope for wider accessibility. However, such innovations are still under development and not yet broadly available for all mRNA-based products. Until more thermostable solutions become mainstream, the cold chain will remain a critical limiting factor. Addressing this issue is essential for expanding the reach of mRNA Vaccines globally, especially in regions with fragile healthcare infrastructure.

Key Market Trends

Diversification Into Therapeutics Beyond Vaccines

Diversification into therapeutics beyond vaccines is transforming the landscape of the global mRNA Vaccine market. While initial breakthroughs centered on infectious diseases like COVID-19, mRNA technology is now being harnessed for a broad spectrum of therapeutic applications. Oncology is a primary focus, where personalized cancer vaccines use patient-specific tumor mutations to train the immune system to target malignant cells. Companies like BioNTech and Moderna are actively developing clinical programs aimed at various cancers, including melanoma, lung, and pancreatic types.

The appeal of mRNA in oncology lies in its adaptability and speed. Developers can rapidly design and produce vaccines that match an individual's cancer profile, offering a level of customization that traditional therapies cannot provide. This approach not only enhances treatment precision but also opens the door to more effective combination therapies with checkpoint inhibitors or immunomodulators. In genetic disorders, mRNA therapies are being explored as a way to replace faulty or missing proteins. Diseases such as cystic fibrosis or certain metabolic conditions are potential targets, where mRNA could provide temporary yet repeated protein correction. This method offers a less invasive and potentially safer alternative to gene editing technologies. Autoimmune diseases are also emerging as a new frontier. mRNA may help retrain the immune system to tolerate self-antigens, offering novel treatments for conditions like multiple sclerosis or type 1 diabetes. This shift toward broader therapeutic use signals a long-term evolution of the mRNA platform beyond its vaccine origins.

Key Market Players

  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • CureVac N.V.
  • Daiichi Sankyo Company Limited.
  • Ethris GmbH
  • GlaxoSmithKline plc
  • Gennova Biopharmaceuticals Ltd
  • Moderna, Inc.
  • Pantherna Therapeutics GmbH
  • Providence Therapeutics

Report Scope:

In this report, the Global MRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Vaccine Market, By mRNA Type:

  • Nucleoside-modified mRNA
  • Unmodified mRNA
  • Self-Amplifying mRNA

mRNA Vaccine Market, By Application:

  • COVID-19 mRNA Vaccines
  • Non COVID-19 mRNA Vaccines
  • Others

mRNA Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MRNA Vaccine Market.

Available Customizations:

Global MRNA Vaccine Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Study Type
  • 4.7. Breakdown of Pipeline, By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.4. By Company (20242)
  • 6.3. Product Market Map
    • 6.3.1. By mRNA Type
    • 6.3.2. By Application
    • 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States mRNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By mRNA Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Canada mRNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By mRNA Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Mexico mRNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By mRNA Type
        • 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France mRNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By mRNA Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany mRNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By mRNA Type
        • 8.3.2.2.2. By Application
    • 8.3.3. United Kingdom mRNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By mRNA Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy mRNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By mRNA Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Spain mRNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By mRNA Type
        • 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China mRNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By mRNA Type
        • 9.3.1.2.2. By Application
    • 9.3.2. India mRNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By mRNA Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Japan mRNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By mRNA Type
        • 9.3.3.2.2. By Application
    • 9.3.4. South Korea mRNA Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By mRNA Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Australia mRNA Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By mRNA Type
        • 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mRNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By mRNA Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina mRNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By mRNA Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia mRNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By mRNA Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa mRNA Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By mRNA Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By mRNA Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE mRNA Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By mRNA Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Merger Acquisition
  • 13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Arcturus Therapeutics Holdings Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Product Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. BioNTech SE
  • 16.3. CureVac N.V.
  • 16.4. Daiichi Sankyo Company Limited.
  • 16.5. Ethris GmbH
  • 16.6. GlaxoSmithKline plc
  • 16.7. Gennova Biopharmaceuticals Ltd
  • 16.8. Moderna, Inc.
  • 16.9. Pantherna Therapeutics GmbH
  • 16.10. Providence Therapeutics

17. Strategic Recommendations

18. About Us & Disclaimer